(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 November 2005 (17.11.2005)

PCT

(10) International Publication Number
WO 2005/107758 A1

(51) International Patent Classification[7]: A61K 31/505, C07D 239/94, A61P 43/00, 35/00

(21) International Application Number: PCT/IB2005/001139

(22) International Filing Date: 25 April 2005 (25.04.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/568,872 6 May 2004 (06.05.2004) US

(71) Applicant *(for all designated States except US)*: **WARNER-LAMBERT COMPANY LLC** [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **FAKHOURY, Stephen, Alan** [US/US]; Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48105 (US). **LEE, Helen, Tsenwhei** [US/US]; Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48105 (US). **REED, Jessica, Elizabeth** [GB/US]; Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48105 (US). **SCHLOSSER, Kevin, Matthew** [US/US]; Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48105 (US). **SEXTON, Karen, Elaine** [US/US]; Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48105 (US). **TECLE, Haile** [US/US]; Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48105 (US). **WINTERS, Roy, Thomas** [US/US]; Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Road, Anne Arbor, MI 48105 (US).


(74) Agents: **FULLER, Grover, F., Jr.** et al.; Pfizer Inc., 201 Tabor Road, Morris Plains,NJ 07950 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH,

[Continued on next page]

(54) Title: 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES



(I)

(57) Abstract: The invention provides quinazoline compounds of the formula: wherein R_1 is halo; R_2 is H or halo; R_3 is a) C_1-C_3 alkyl, optionally substituted by halo; or b) -$(CH_2)_n$-morpholino, -$(CH_2)_n$-piperidine, -$(CH_2)_n$-piperazine, -$(CH_2)_n$-piperazine-N(C_1-C_3 alkyl), -$(CH_2)_n$-pyrrolidine, or -$(CH_2)_n$ imidazole; n is 1 to 4; R_4 is -$(CH_2)_m$-Het; Het is morpholine,piperidine, piperazine, piperazine-N(C_1-C_3 alkyl), imidazole,pyrrolidine, azepane, 3,4-dihydro-2H-pyridine, or 3,6-dihydro-2H-pyridine, each optionally substituted by alkyl, halo, OH, NH_2, NH(C_1-C_3 alkyl) or N (C_1-C_3 alkyl)$_2$; m is 1-3; and X is O, S or NH; or a pharmaceutically acceptable salt thereof, as well as processes and intermediate compounds for making them, useful pharmaceutical compositions and methods of using the compounds in the treatment of proliferative diseases.

WO 2005/107758 A1

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.